Vote Scores

Home / Companies / Nautilus Biotechnology, Inc. / 17 Jun 2026

Meeting · year to 30 June 202671 filers reporting

Nautilus Biotechnology, Inc.: meeting of 17 Jun 2026

Votes reported on Form N-PX, item by item

71 Form N-PX filers reported votes at the Nautilus Biotechnology, Inc. meeting of 17 Jun 2026. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 48.1% of reported votes for; 9 filers withheld from or voted against at least one nominee.

50 vote records from 14 filers. 8 of the 14 filers that marked the item either way voted against management.

42.9% for0.0% against57.1% other57.1% against management14 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

92 vote records from 70 filers. 2 of the 60 filers that marked the item either way voted against management. 10 filers reported this item without a management mark.

82.9% for2.9% against14.3% other3.3% against management70 filers100.0% for0.0% against0.0% other0.0% against management46,725,156 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 55 filers; three years: 5 filers; not applicable: 2 filers; did not vote: 1 filer; for: 1 filer; take no action: 1 filer.

95 vote records from 71 filers. 5 of the 61 filers that marked the item either way voted against management. 10 filers reported this item without a management mark.

1.4% for0.0% against98.6% other8.2% against management71 filers25.4% for0.0% against74.6% other1.2% against management46,864,949 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

25 vote records from 14 filers. 0 of the 14 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management14 filers100.0% for0.0% against0.0% against management3,554,336 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForForSplit or no voteFor
BlackRock and iSharesForForSplit or no voteFor
FidelityForForSplit or no voteFor
DimensionalAbstain or withhold *ForSplit or no vote *For
State Street and SPDRNo reportForSplit or no voteNo report
American CenturyAbstain or withhold *ForSplit or no voteFor
Charles SchwabNo reportForSplit or no voteNo report
Nuveen and TIAANo reportForSplit or no voteNo report
Goldman SachsForForSplit or no voteFor
Jackson National fundsAbstain or withhold *ForSplit or no vote *For
Northern Trust and FlexSharesNo reportForSplit or no voteNo report
Lincoln FinancialAbstain or withhold *ForSplit or no vote *For
Victory CapitalAbstain or withhold *ForSplit or no voteFor
BNY MellonNo reportForSplit or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Nautilus Biotechnology, Inc. meeting?

71 Form N-PX filers reported votes at the meeting of 17 Jun 2026. On say-on-pay, 2 of 60 voted against management (3.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Nautilus Biotechnology, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Nautilus Biotechnology, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Nautilus Biotechnology, Inc. with a meeting date within three days of 17 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.